Table 2.
Boron biodistribution of cis-ABCHC, trans-ABCHC, and BPA in B16 melanoma bearing mice.
| Mean Boron Concentration (μg/g tissue) ± SDb |
Ratios |
|||||||
|---|---|---|---|---|---|---|---|---|
| Compounda | Tumor | Blood | Liver | Kidney | Spleen | Brain | T/Bl | T/Br |
| cis-ABCHC | 31.7 ± 11.2 | 2.1 ± 0.9 | 3.6 ± 2.1 | 5.8 ± 1.6 | 4.1 ± 1.5 | 2.6 ± 0.6 | 15.1 | 12.2 |
| trans-ABCHC | 13.9 ± 2.7* | 3.2 ± 0.6 | 4.7 ± 1.0 | 8.3 ± 3.2 | 5.3 ± 1.4 | n.d. | 4.3 | - |
| BPA | 28.6 ± 4.6 | 5.3 ± 0.8* | 5.3 ± 1.0 | 18.9 ± 1.3* | 14.1 ± 5.3* | n.d. | 5.4 | - |
All compounds at a dose of 24 mg B equivalent/kg b.w. were administered i.p. and animals were euthanized at 2.5 hrs post-dosing.
Boron concentrations were determined by means of ICP-OES. Means and standard deviations were calculated for each group of 4 mice. “n.d.” designates “not determined.” Ratios of boron concentrations in tumor (T) to blood (Bl) and tumor to brain (Br) were calculated.
Boron concentrations for the different compounds in each group of tissue and blood samples were compared using analysis of variance (ANOVA) and Tukey’s post hoc test for multiple comparisons. A p value of less than 0.05 was considered significant. The tumor uptake value of trans-ABCHC was significantly different (p<0.05) from cis-ACCHC and BPA.